Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
In the US, the trivalent form of Flublok was approved for use in persons aged 18-49 years in 2013. The quadrivalent form was approved in October 2016 in the US for use in people aged 18 years and older. In the EU, Protein Sciences halted the development of trivalent Flublok to pursue a quadrivalent vaccine in the coming years.
Flublok (recombinant quadrivalent influenza vaccine [QIV]; Sanofi) was the first influenza vaccine manufactured without using the traditional egg-based process, and therefore does not contain any egg proteins. As Flublok does not contain any egg components, this makes it suitable for people with egg allergies.
Key Topics Covered
- Drug Overview
- Product Profiles
- Flublok: Seasonal influenza vaccines
List of Tables
Table 1: Flublok drug profile
Table 2: Approval history of Flublok for seasonal influenza vaccination
Table 3: Late-phase trials of Flublok for seasonal influenza vaccination
Table 4: Flublok for seasonal influenza - SWOT analysis
For more information about this report visit https://www.researchandmarkets.com/r/5br4i